Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis
- Xiaohui Liang†1,
- Danying Wang†2,
- Yan Wang†1,
- Zhiqiang Zhou†1,
- Juan Zhang†1 and
- Jinsong Li1Email author
© Liang et al.; licensee BioMed Central Ltd. 2012
Received: 25 May 2012
Accepted: 9 July 2012
Published: 18 July 2012
To investigate the expression of Aurora Kinase A and B in patients with chondrosarcoma and consider it as a prognostic marker and molecular target of therapy.
To evaluate the relationship of the Aurora Kinase A and B and the clinical pathological parameters and prognosis of chondrosarcoma. 72 case chondrosarcoma and 42 case chondroma were performed immunohistochemistry on the tissue microarray paraffin sections. The survival time of patients was followed-up.
The expression of Aurora Kinase A and B in chondrosarcoma was significantly higher than that in chondroma (p<0.01). There were differences about the expression of Aurora Kinase A and B in chondrosarcoma between the recurrence group and the non-recurrence group, metastatic group and non-metastatic group (p<0.05), but not age and gender (p>0.05). The expression of Aurora Kinase A and B were significantly lower in group low grade conventional chondrosarcoma than that in groups medium and high grade conventional chondrosarcoma (p<0.01). The expression of Aurora Kinase A and B in chondrosarcoma showed a positive correlation (p<0.01). According to the Kaplan Meier analysis and multivariate Cox regression analysis, the survival rate was significantly different between the patients with positive Aurora Kinase A and the patients with negative expression (p<0.05) and Aurora Kinase A expression was an independent risk marker of survival(HR=11.263, 95%CI: 2.317–54.748, P=0.003).
Both the Aurora Kinase A and B might involve in the oncogenic, invasive and metastatic process of chondrosarcoma; however, the mechanism is still unclear. The Aurora Kinase A and B could be used as a new prognostic marker and molecular therapeutic target for chondrosarcoma.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9101494267377096.
Chondrosarcoma is the second most common malignant bone tumors following the osteosarcoma in China , in which the tumor cells can generate a lot of bone matrix. To some extent, the chondrosarcoma is not sensitive to chemotherapy and radiation therapy, due to its characteristic of increase of extracellular matrix, decrease of divided cells vessels. To date, the dominant clinical treatment for chondrosarcoma is surgical resection; however, the recurrence rate is too high (20%). Therefore, there is an urgent need of a new therapy for patients with chondrosarcoma, especially for patients with recurrence.
Aurora Kinase family is a newly discovered serine and threonine kinase family, which regulates the function of centriole and microtubule, and plays an important role in maintaining the normal mitosis and cell cycle. However, the disordered expression of Aurora Kinase promoted the oncogenesis. The Aurora Kinase family consists of 3 members in mammal: Aurora Kinase A, B and C. In recent study, it showed that tumorigenesis appeared by transfection of the Aurora Kinase A gene into 3T3 cells in nude mouse , and the Aurora Kinase A gene had been identified as a new oncogene. Aurora Kinase A gene was highly expressed in various malignant tumors, such as oophoroma, colorectal cancer and acute myeloid leukemia [3–5]. Aurora Kinase B was also highly expressed in many tumor tissues, including oral cancer, the non-small-cell lung carcinoma and hepatocellular carcinoma [6–8], etc. Furthermore, it has been showed that the activity inhibitors of Aurora Kinase could inhibit the growth of cancer cells, and some inhibitors have been applied in the pre-clinical experimental stage [9, 10].
Whether the Aurora Kinase A and B were expressed in the chondrosarcoma is still unknown, in this study, we investigated the expression of the Aurora Kinase A and B in the chondrosarcoma tissues by immunohistochemistry and analyzed its clinical significance; and we also followed-up the patients.
Materials and methods
Clinicopathological parameters of the involved chondrosarcoma cases
average median survival time
average follow-up interval
Tissue microarray (TMA)
Firstly, all samples were performed hematoxylin and eosin staining (HE), then two fields were chosen from all HE slides and the corresponding spots were marked on the surface of the paraffin block. Next the marked areas were punched out and placed into the recipient block side by side with the tissue microarray punching instrument. Each tissue point was 2 mm in diameter and assigned with a unique tissue microarray location number, which was linked to a database containing other clinicopathologic data.
The streptavidin-peroxidase-biotin (SP) immunohistochemical method was used to study the expression of Aurora Kinase A and B in the tissue microarrays. The paraffin specimens were cut into 4 μm sections and stayed at 60°C for 60 min. Then the sections were dewaxed and rehydrated. Next, antigen retrieval was achieved by microwave using EDTA buffer for 2.5 min and then cooled at room temperature for 30 min. After washing with PBS for 3 times, the endogenous peroxidase was blocked with 3% hydrogen peroxide, followed by incubation with goat serum to block nonspecific binding. Then rabbit anti-human polyclonal Aurora-A antibody (1:800; ABGENT,American) and rabbit anti-human polyclonal Aurora-B antibody (1:1000; ABGENT,American) were incubated with the sections overnight at 4°C. After washing, the tissue sections were treated with biotinylated anti-rabbit secondary antibody (Zhongshan Biotechnology Company, Beijing, China) for 30 min; then incubated with streptavidin-horseradish peroxidase complex for 20 min. At last, the sections were developed with diaminobenzidine (DAB) and counterstained with hematoxylin. For negative controls, the Aurora-A antibodies and the Aurora-B antibodies were replaced by PBS.
Evaluation of immunohistochemical staining
3 visual fields (400×) were randomly chosen and cells were counted with Image-Pro Plus (Media Cybernetics, Bethesda, MD). The Aurora Kinase A is expressed in cytoplasm and the Aurora Kinase B is expressed in both cytoplasm and nucleus. Grade and score by the intensity of staining: 0 point for colorless, 1 point for light yellow, 2 points for claybank and 3 points for brown; then grade by the ratio of positive cell: 0 point for no positive staining cells, 1 point for positive ratio ≤10%, 2 points for 11%–50%, 3 points for 51%–75% and 4 points for>75%. At last multiply the 2 score system: ≤3 points for negative, >3 points for positive. The slides were reviewed and scored independently by two observers who blinded to the patients’ information.
Data were analyzed by SPSS17.0 statistical analysis software. A P<0.05 was considered statistically significant.
Expression of Aurora Kinase A and B in chondrosarcoma and chondroma
Expression of Aurora Kinase A and B in the tissue of chondrosarcoma and chondroma
Aurora Kinase A positive
Aurora KinaseA negative
Aurora KinaseB positive
Aurora KinaseB negative
Expression of Aurora Kinase A and B and chondrosarcoma
Association of Aurora Kinase A,B expression with the clinicopathological features of the chondrosarcoma
Correlation of the expression of Aurora Kinase A and B in chondrosarcoma
Aurora Kinase A
Aurora Kinase B
Multivariate Cox regression analysis of Aurora Kinase A and B and clinicopathological features
95.0%CI for HR
Aurora Kinase A
Aurora Kinase B
Tumor is a type of general, systematic and step-by-step developing disease involving lots of factors; it is caused by the mutation of the oncogenes and disorders of some genes . Chondrosarcoma derived from the chondrocytes, which is a primary malignant tumor, which consists of the tumorous chondrocytes and cartilage matrix. The prevalence of chondrosarcoma was approximately 20% of all the primary bone malignant tumors . At present, the research on molecular targeted therapy for malignant tumors is popular all over the world. The molecular targeted therapy mainly corrects the abnormal signaling pathways of the tumor, with the characteristics of high selectivity, hypotoxicity and high therapeutic index . The abnormal expression of Aurora Kinase family is closely associated with the development of tumor, because of the crucial role of Aurora Kinase family plays in the mitosis and cell cycle. In this report, we investigated the expression of Aurora Kinase A and B in chondrosarcoma and provided a strong support for the development of the new drugs of molecular targeted therapy for chondrosarcoma.
Aurora Kinase A is a member of Aurora Kinase family which has been considered as a crucial factor to regulate mitosis. It participates in the maturation and segregation of centriole, the assembly and stabilization of spindle, the condensation of chromosome and the converging and stabilization of the median plate, etc. However, its overexpression can result in the augmentation of centriole, the formation of multiploid and the loss of p53. Through studying the expression profile of Aurora Kinase A in various normal tissues, we found that Aurora Kinase A mRNA only had a relative low expression level in thymus, but was barely detected in other tissues, such as the brain, lung, intestine, spleen and testis. In various malignant tumors Aurora Kinase A had been found overexpression. Marco et al. reported that the expression of Aurora Kinase A was up-regulated in hepatoma especially in the type of poorly differentiated tissues . Rudolf et al. reported that the expression of Aurora Kinase A mRNA was up-regulated in the head and neck carcinoma . Therefore, it could be considered as a prognostic factor for malignant tumors.
Our results showed that the expression of Aurora Kinase A was very low in chondroma tissues, while it was strongly expressed in chondrosarcoma; which indicated that Aurora Kinase A played an important role in the initial and developmental stage of the chondrosarcoma. The results also showed that the expression of Aurora Kinase A was significant different between the recurrence group and the non-recurrence group, the metastatic group and non-metastatic group, suggesting that the high expression of Aurora kinase A is associated with oncogenesis and the grade of the malignancy and differentiation of chondrosarcoma. However, there was no correlation of the expression of Aurora Kinase A and the age, gender, the site and size of the tumor. Combination of immunohistochemisty and follow-up data we can see that there was significant difference of the overall survival rate between the Aurora Kinase A positively expressed group and the negatively expressed group.
In addition, it has been reported that the high expression of Aurora Kinase A in esophageal squamous cell carcinoma could significantly promote the proliferation of tumor cells and increase the resistance to apoptosis induced by DDP and ultraviolet radiation . Takayuki et al. reported that Aurora Kinase inhibitor ZM447439 could inhibit the growth of leukemia cells . Thereforethe inhibition of the activity of Aurora Kinase A could lead to the tumor cell apoptosis instead of malignant proliferation. Accordingly, Aurora Kinase A is expected to become the new target for chondrosarcoma. In the further study, we will further conduct related experiments to identify whether the Aurora Kinase A inhibitor can be used as the molecular target treatment for chondrosarcoma.
The Aurora Kinase B is the component of the chromosome passenger protein complex which participate in the chromosome condensation, spindle assembly, segregation of sister chromatids and cytocinesis. Recent studies reported that Aurora Kinase B expressed abnormally in various malignant tumors, such as breast cancer  and acute lymphatic leukemia . Our results showed that in chondroma tissues the expression of Aurora Kinase B was barely detected, however, most of the chondrosarcoma tissue cells expressed positively, even 100% positive in stage III.It indicated that Aurora Kinase B played an important role in the process of the oncogenesis and development of chondrosarcoma. Moreover, we found the positive expression of Aurora Kinase B was significant different between the metastatic group and non-metastatic group and the recurrence group and the non-recurrence group, which suggests that Aurora Kinase B impacts on the invasiveness of chondrosarcoma. Ren et al. reported that it might enhance the sensitivity of ovarian cancer cell A2780 against chemotherapy to paclitaxel and increase the apoptosis by application of AURKB siRNA to A2780, indicating that inhibit of Aurora Kinase B could finally restrain the neoplastic growth by inducing apoptosis of tumor cells . A variety of Aurora Kinase inhibitors have been developed, such as hesperetin against Aurora Kinase B, quinazoline against Aurora Kinase A and B simultaneously and vX-680 against Aurora Kinase A, B and C; besides, some inhibitors have been applied in pre-clinical and I,II stage clinical trials . In the future, our group will study whether Aurora Kinase B inhibitors can inhibit the growth and proliferation of chondrosarcoma cells in vitro and in vivo. Dual inhibitors may be a better choice due to the consistent expression of Aurora Kinase A and Aurora Kinase B.
Our study found that the expression of Aurora Kinase A and B was significantly up-regulated in chondrosarcoma, and the expression of Aurora Kinase A and B was correlated with the recurrence and metastasis of chondrosarcoma. Which demonstrate that Aurora Kinase A and B play an important role in the formation and development of chondrosarcoma. In addition, survival analysis and multivariate Cox regression analysis showed that Aurora Kinase A also affected patients’ outcome. Therefore, Aurora kinase A can be used to predict the prognosis of patients with chondrosarcoma.
The fund of this work was supported by Department of Pathology, Qilu Hospital of Shandong University.
- Jemal A, Siegel R, Ward E: Caner statistics. CA Cancer J Clin. 2006, 56: 106-130. 10.3322/canjclin.56.2.106.View ArticlePubMedGoogle Scholar
- Takayuki I: Aurora kinase as an anti-cancer target. Cancer letters. 2008, 262: 1-9. 10.1016/j.canlet.2008.01.005.View ArticleGoogle Scholar
- Silke L, Yi S, Uta J: Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy. Clin Cancer Res. 2007, 13: 4083-4091. 10.1158/1078-0432.CCR-06-2775.View ArticleGoogle Scholar
- Yoshifumi B, Katsuhiko N, Kaori S: Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009, 11: 418-425.View ArticleGoogle Scholar
- Takayuki I, Yang J, Chie N: Anovel treatment strategy targeting Aurora Kinases in acute myelogenous leukemia. Mol Cancer Ther. 2007, 6: 1851-1857. 10.1158/1535-7163.MCT-07-0067.View ArticleGoogle Scholar
- Qi GY, Ogawa I, Kudo Y: Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch. 2007, 450: 297-302. 10.1007/s00428-006-0360-9.View ArticlePubMedGoogle Scholar
- Barbara V, Joost J, Oudejans : Frequent overexpression of aurora B kinase, a novel drug target, in non-small eell lung carcinoma patients. Mol Cancer Ther. 2006, 5: 2905-2913. 10.1158/1535-7163.MCT-06-0301.View ArticleGoogle Scholar
- Arihiro A, Shinji T, Mahmut Y: The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2010, 52: 63-71. 10.1016/j.jhep.2009.10.013.View ArticleGoogle Scholar
- Hiroshi K, Subrata S: Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta. 2010, 1799: 829-839. 10.1016/j.bbagrm.2010.09.004.View ArticleGoogle Scholar
- David B, Jos B, Jan S: Clinical experience with aurora kinase inhibitors:a Review. Oncologist. 2009, 14: 780-793. 10.1634/theoncologist.2009-0019.View ArticleGoogle Scholar
- Gengyin Z, Peng G: The derivative of molecular pathology——the inevitable development track of the pathology. Journal of Shandong University(Health Sciences). 2011, 49: 63-66.Google Scholar
- Zhifu W, Zhiyan L: Throat chondrosarcomas: 2 cases report. Journal of Shandong University(Health Sciences). 2003, 41: 96-97.Google Scholar
- Marco LI, Valentina M, Silvia S: Aurora kinase a expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. J Transl Med. 2011, 9: 100-106. 10.1186/1479-5876-9-100.View ArticleGoogle Scholar
- Rudolf R, Peter G, Uta J: Aurora kinase a messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006, 12: 5136-5141. 10.1158/1078-0432.CCR-05-1650.View ArticleGoogle Scholar
- Wang XX, Liu R, Jin SQ: Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell line. Cell Res. 2006, 16: 356-366. 10.1038/sj.cr.7310046.View ArticlePubMedGoogle Scholar
- Tehatehou S, Wirtenberger M, Hernnlinki K: Aurora Kinase A and B and familial breast cancer risk. Cancer Lett. 2007, 247: 266-272. 10.1016/j.canlet.2006.05.002.View ArticleGoogle Scholar
- Ikezoe T, Yang J, Nishioka C: A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther. 2007, 6: 1851-1857. 10.1158/1535-7163.MCT-07-0067.View ArticlePubMedGoogle Scholar
- Lirong R, Minglin L, Lan X: Effect of RNAi targeting Aurora B on the paclitaxel chemosensitivity in ovary cancer cell line A2780. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong. 2011, 40: 651-655.Google Scholar
- Giannis M, Evangelos T, Meletios-Athanassios D: Aurora kinase as targets for cancer therapy. Cancer Treat Rev. 2008, 34: 175-182. 10.1016/j.ctrv.2007.09.005.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.